Phase 3 ECHO Trial: Study Design and Efficacy Data

Opinion
Video

The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study.

  1. What are your initial impressions of the efficacy data from ECHO?
  2. How did COVID impact OS for this trial data? 
  3. Do you have clinical experience with BTKi’s in the frontline setting?
    1. If so, please share your experience.
Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
2 KOLs are featured in this series
2 KOLs are featured in this series
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Related Content